Aging Technology has a Multiplier Effect Like Investment in Space Technology
December 09, 2024 07:00 ET
|
Posit Science
WASHINGTON, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Dr. Henry Mahncke, CEO of Posit Science, the maker of the brain health and fitness app BrainHQ, will address the 6th Annual What’s Next Innovation...
Firefly Neuroscience Reports Third Quarter 2024 Results and Provides Stockholder Update
November 14, 2024 17:30 ET
|
Firefly Neuroscience, Inc.
Company successfully listed on Nasdaq under the symbol “AIFF” Partnered with multiple neuroscience pharmaceutical companies, including Bright Minds Bioscience, and neurologists to advance Company’s...
DiagnaMed Files U.S. Patent Application for Novel Methods of Producing Molecular Hydrogen
November 07, 2024 08:00 ET
|
DiagnaMed Holdings Corp.
Advancing molecular hydrogen for neurological and mental health disorders Expects its molecular hydrogen product to be ready for use in December 2024 TORONTO, Nov. 07, 2024 (GLOBE NEWSWIRE) --...
Firefly Neuroscience to Participate in the 8th Annual Florida Capital Event
November 06, 2024 09:00 ET
|
Firefly Neuroscience, Inc.
TORONTO, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
DiagnaMed Advancing the Medical Potential of Hydrogen
October 30, 2024 08:00 ET
|
DiagnaMed Holdings Corp.
TORONTO, Oct. 30, 2024 (GLOBE NEWSWIRE) -- DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a life sciences company focused on brain health, announces its...
Firefly Neuroscience Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
October 25, 2024 16:10 ET
|
Firefly Neuroscience, Inc.
TORONTO, Oct. 25, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions that...
Angelini Pharma stipula un accordo di opzione di licenza esclusiva con Cureverse per lo sviluppo e la commercializzazione a livello mondiale di una nuova e innovativa sostanza per la salute del cervello in fase clinica
October 21, 2024 00:00 ET
|
Angelini Pharma
L'accordo conferisce ad Angelini Pharma un'opzione di licenza esclusiva per lo sviluppo e la commercializzazione di CV-01, un nuovo composto in fase clinica 1 con un grande potenziale per il...
Angelini Pharma Enters Into An Exclusive Option Agreement With Cureverse to License Global Development and Commercialization Rights For A Novel and Innovative Clinical-Stage Brain Health Asset
October 21, 2024 00:00 ET
|
Angelini Pharma
Angelini Pharma Enters Into Exclusive Option Agreement With Cureverse to License Global Development & Commercialization Rights
For Brain Health Asset
Firefly Neuroscience Advances AI-Driven BNA™ Technology in Neuroscience Drug Development after Completing Successful Research Collaborations with Takeda and Novartis
September 20, 2024 09:00 ET
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 20, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...
Firefly Neuroscience Announces Partnership with Zeto to Integrate and Distribute its BNA™ Technology with Zeto's FDA-Cleared EEG Device Platform
September 10, 2024 09:00 ET
|
Firefly Neuroscience, Inc.
TORONTO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence (“AI”) company developing innovative solutions...